 HOUSTON, Oct. 29, 2020 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. Nasdaq:BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock or pre-funded warrants to purchase common stock in lieu thereof and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock or pre-funded warrant in lieu thereof is being sold together with one warrant to purchase one share of common stock at a combined effective price of 6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicums existing healthcare-dedicated institutional investors. 